


RECEIVED
AUG 15 2002
TECH CENTER 1600/2900

Form PTO/SB/08B		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/087,268
		Filing Date	March 1, 2002
		First Named Inventor	Elizabeth E. Powell
		Group Art Unit	1645
		Examiner Name	Not yet assigned
Sheet	1	of	2
		Attorney Docket Number	10338-3U1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	AWAD et al., "Genotypic variation in the transforming growth factor-β1 gene: association with transforming growth factor-β1 production, fibrotic lung disease, and graft fibrosis after lung transplantation," Transplantation 66(8):1014-1020 (1998).	
	BAKER et al., "Transducers of life and death: TNF receptor superfamily and associated proteins," Oncogene 12:1-9 (1996).	
	BATALLER et al., "Angiotensin II induces contraction and is mitogenic for cultured human hepatic stellate cells. Antagonization by losartan and modulation by vasodilators," Hepatology 28:437A (1998) (Abstract only).	
	BEDOSSA et al., "Transforming growth factor-β(TGF-β): a key-role in liver fibrogenesis," J. Hepatol. 22(Suppl. 2):37-42 (1995).	
	CAMBIEN et al., "Polymorphisms of the transforming growth factor-β1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study," Hypertension 28(5):881-887 (1996).	
	CASTILLA et al., "Transforming growth factors β1 and α in chronic liver disease - effects of interferon alfa therapy," N. Engl. J. Med. 324(14):933-940 (1991).	
	CZAJA et al., "Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis," Gastroenterology 117(3):645-652 (1999).	
	EDWARDS-SMITH et al., "Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa," Hepatology 30(2):526-530 (1999).	
	FRIEDMAN, "Cytokines and fibrogenesis," Semin. Liver Dis. 19(2):129-140 (1999).	
	GAYAGAY et al., "Elite endurance athletes and the ACE I allele - the role of genes in athletic performance," Hum. Genet. 103:48-50 (1998).	
	GIBBONS et al., "vascular smooth muscle cell hypertrophy vs. hyperplasic - autocrine transforming growth factor-β, expression determines growth response to angiotensin II," J. Clin. Invest. 90:456-461 (1992).	
	HAHN et al., "Stimulation of autocrine platelet-derived growth factor aa-homodimer and transforming growth factor β in vascular smooth muscle cells," Biochem. Biophys. Res. Comm. 178(3):1451-1458 (1991).	
	HOURIGAN et al., "Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis," Hepatology 29(4):1215-1219 (1999).	
	HUANG et al., "Tumour necrosis factor-α polymorphism and secretion in myasthenia gravis," J. Neuroimmunol. 94:165-171 (1999).	
	HUANG et al., "Markers in the promoter region of interleukin-10 (IL-10) gene in myasthenia gravis: implications of diverse effects of IL-10 in the pathogenesis of the disease," J. Neuroimmunol. 94:82-87 (1999).	
	INOUE et al., "A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro," J. Clin. Invest. 99(7):1786-1797 (1997).	
	KIM et al., "Post-transcriptional regulation of the human transforming growth factor-β1 gene," J. Biol. Chem. 267(19):13702-13707 (1992).	
	KIM et al., "Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-β1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats," J. Pharm. Exp. Ther. 273(2):509-515 (1995).	
	LEE et al., "Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney," J. Clin Invest. 96:953-964 (1995).	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--



RECEIVED
AUG 15 2002
TECH CENTER 1600/2900

Form PTO/SB/088		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/087,268
		Filing Date	March 1, 2002
		First Named Inventor	Elizabeth E. Powell
		Group Art Unit	1645
		Examiner Name	Not yet assigned
		Attorney Docket Number	10338-3U1
Sheet	1	of	2

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	LI et al., "TGF- β_1 DNA polymorphisms, protein levels, and blood pressure," Hypertension 33:271-275 (1999).	
	LINDPAINTNER et al., "A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease," N. Engl. J. Med. 332(11):706-711 (1995).	
	LYMPANY et al., "Rapid genotyping of transforming growth factor β_1 gene polymorphisms in a UK caucasoid control population using the polymerase chain reaction and sequence-specific primers," Tissue Antigens 52:573-578 (1998).	
	MANTEL et al., "Statistical aspects of the analysis of data from retrospective studies of disease," J. Nat. Cancer Ins. 22(4):719-748 (1959).	
	MIYAZONO et al., "Latent high molecular weight complex of transforming growth factor β_1 - purification from human platelets and structural characterization," J. Biol. Chem. 263(13):6407-6415 (1988).	
	NAKATSUKASA et al., "Transforming growth factor- β_1 and type I procollagen transcripts during regeneration and early fibrosis of rat liver," Lab. Invest. 63(2):171-180 (1990).	
	NAKATSUKASA et al., "Cellular distribution of transforming growth factor- β_1 and procollagen types I, III, and IV transcripts in carbon tetrachloride-induced rat liver fibrosis," J. Clin. Inv. 85:1833-1843 (1990).	
	NOBLE et al., "Angiotensin II in renal fibrosis: should TGF- β rather than blood pressure be the therapeutic target?," Seminars in Nephrology 17(5):455-466 (1997).	
	PERREY et al., "Genotyping for polymorphisms in interferon- γ , interleukin-10, transforming growth factor- β_1 and tumour necrosis factor- α genes: a technical report," Transpl. Immunol. 6:193-197 (1998).	
	PERNEGER, "What's wrong with Bonferroni adjustments," BMJ 316:1236-1238 (1998).	
	POYNARD et al., "Natural history of liver fibrosis progression in patients with chronic hepatitis C," Lancet 349: 825-832 (1997).	
	RIGAT et al., "Insertion/deletion polymorphism in the angiotensin I-converting enzyme - the accounting for half the variance of serum enzyme levels," J. Clin. Invest. 86:1343-1346 (1990).	
	ROTHMAN, "No adjustments are needed for multiple comparisons," Epidemiology 1(1):43-46 (1990).	
	SAVITZ et al., "Multiple comparisons and related issues in the interpretation of epidemiologic data," Am. J. Epidemiol. 142(9):904-908 (1995).	
	SCHEUER, "Classification of chronic viral hepatitis: a need for reassessment," J. Hepatology 13:372-374 (1991).	
	TANAKA et al., "The tumor necrosis factor- α promoter correlates with progression of primary biliary cirrhosis," J. Hepatology 30:826-829 (1999).	
	TURNER et al., "An investigation of polymorphism in the interleukin-10 gene promoter," Eur. J. Immunogenet. 24:1-8 (1997).	
	WANG et al., "Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells," J. Biol. Chem. 273(1):302-308 (1998).	
	WILSON et al., "Single base polymorphism in the human tumour necrosis factor alpha (TNF α) gene detectable by NcoI restriction of PCR product," Hum. Mol. Genet. 1(5):353 (1992) (Abstract only).	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--